Compounded Tirzepatide How It Works: Mechanism of Action Explained

Introduction

Tirzepatide is a dual incretin agonist. It binds and activates both the GIP receptor and the GLP-1 receptor with engineered selectivity. The molecule is a 39-amino-acid peptide with a fatty acid tail that binds albumin in blood, giving it a 5-day half-life and enabling once-weekly dosing. The compounded version contains the same active ingredient as Mounjaro® and Zepbound®, prepared by a 503A or 503B pharmacy under individualized prescription.

Activating both receptors produces stronger appetite suppression, greater insulin response, and more weight loss than activating GLP-1 alone. SURMOUNT-1 (Jastreboff et al. 2022, NEJM) showed 20.9% mean weight loss on tirzepatide 15 mg at 72 weeks vs 14.9% on semaglutide 2.4 mg in STEP 1.

This article walks through GIP biology, why dual agonism matters, where the drug acts in the body, and what changes at each step from injection to clinical effect.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is GIP and Why Does Adding It Matter?

GIP (glucose-dependent insulinotropic polypeptide) is a 42-amino-acid peptide hormone released from K-cells in the proximal small intestine within minutes of eating. Like GLP-1, it amplifies the insulin response to food. Unlike GLP-1, it also stimulates glucagon release in the fasting state, which is why isolated GIP agonists weren’t originally pursued for diabetes therapy.

Quick Answer: Tirzepatide binds both GIP and GLP-1 receptors; semaglutide binds only GLP-1

In combination with GLP-1 activation, GIP’s effects shift. Co-activation enhances insulin secretion more than either alone and contributes to direct effects on adipose tissue including improved lipid handling and reduced inflammation.

The original assumption was that GIP signaling in obesity was dysfunctional and shouldn’t be activated. SURMOUNT and SURPASS trials proved that wrong: GIP plus GLP-1 produces stronger weight loss and metabolic improvement than GLP-1 alone.

How Does Dual Agonism Produce More Weight Loss?

Two mechanisms appear to drive the additional weight loss vs semaglutide:

First, stronger central appetite suppression. GIP receptors in the hypothalamus and area postrema add to GLP-1 effects on satiety and food reward. Brain imaging studies show stronger reduction in reward circuitry activation with dual agonism.

Second, less metabolic adaptation. Caloric restriction normally triggers reduced resting metabolic rate (the body’s adaptive thermogenesis response). Animal models suggest GIP agonism may blunt this adaptation, helping the body burn more calories at rest during weight loss. Human data on this is suggestive but limited.

SURMOUNT-1 enrolled 2,539 adults with overweight or obesity but without diabetes. Mean weight loss at 72 weeks was 15.0% on tirzepatide 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg vs 3.1% on placebo.

What Does Tirzepatide Do at the GLP-1 Receptor?

Tirzepatide activates the GLP-1 receptor with somewhat lower affinity than native GLP-1 or semaglutide. Coupled with high GIP affinity, this asymmetric pattern is intentional. The engineered “imbalance” produces the observed efficacy profile that exceeds equivalent GLP-1 agonist exposure alone.

Downstream effects through the GLP-1 receptor are similar to semaglutide:

• Glucose-dependent insulin secretion from pancreatic beta cells
• Glucagon suppression from alpha cells
• Slowed gastric emptying (similar magnitude to semaglutide, 35-70% in early weeks)
• Central appetite suppression via hypothalamic and brainstem receptors

The GLP-1 portion of tirzepatide’s effect accounts for the majority of weight loss; GIP adds additional benefit.

How Does the GIP Component Change Cardiovascular and Metabolic Outcomes?

The SURPASS-CVOT trial is studying tirzepatide vs dulaglutide in approximately 13,000 adults with type 2 diabetes and elevated cardiovascular risk. Topline results are expected in 2025. This will be the first direct test of whether dual agonism produces stronger cardiovascular outcomes than GLP-1 alone.

Preliminary signals from SURPASS and SURMOUNT trials suggest tirzepatide produces greater improvements in blood pressure (5-8 mmHg systolic), lipids (LDL drop of 5-10 mg/dL), and inflammatory markers vs comparable GLP-1 agonist doses. SUMMIT (Packer 2024, NEJM) showed improved KCCQ scores and reduced clinical events in HFpEF.

For people with diabetes, tirzepatide produces stronger A1c reduction than semaglutide. SURPASS-2 (Frias 2021, NEJM) directly compared the two in 1,879 adults with type 2 diabetes. Tirzepatide 15 mg lowered A1c by 2.3% vs 1.9% with semaglutide 1.0 mg at 40 weeks. Tirzepatide also produced more weight loss (11.2 kg vs 5.7 kg).

What Changes in the Brain on Tirzepatide?

Brain imaging studies (early data, with more in progress) show tirzepatide reduces activation in reward circuitry, particularly in response to food cues. The reduction is somewhat stronger than with GLP-1 alone, consistent with dual receptor engagement in regions like the nucleus accumbens and orbitofrontal cortex.

Patients describe similar but stronger “food noise quieting” compared to semaglutide. Many report not just reduced hunger but loss of food-related thoughts entirely between meals. The interest in highly palatable foods (sweets, salty snacks, alcohol) drops more reliably with tirzepatide.

The same brain regions involved in food reward also process other reward signals, which is why GLP-1 and dual agonists are being explored for alcohol use disorder, smoking cessation, and gambling addiction.

How Does Tirzepatide Affect the Digestive System?

Like semaglutide, tirzepatide slows gastric emptying by 35-70% in the first weeks of treatment. Both early satiety and post-meal glucose responses change as a result. The effect attenuates over time (tachyphylaxis), with gastric emptying partially normalizing after 12-20 weeks even at maintenance dosing.

In the small intestine, tirzepatide alters bile acid metabolism and microbiome composition in ways that may contribute to weight loss and metabolic improvements. The full picture is still being studied, but gut hormone changes beyond the direct receptor effects appear to play a meaningful role.

For most patients, this translates to early satiety after a few bites of food, reduced interest in eating between meals, and altered taste preferences, particularly reduced craving for fatty and sweet foods.

What’s the Cardiovascular and Kidney Evidence?

SURPASS-CVOT cardiovascular outcomes are not yet published but expected in 2025. Cardiovascular signals in completed SURPASS trials (SURPASS 1-5) have been favorable but those trials weren’t powered for hard cardiovascular endpoints.

For kidney function, exploratory analyses from SURPASS-4 (Frias 2021 Lancet) suggested favorable effects on albuminuria and eGFR. Tirzepatide’s effect on the kidney appears similar to semaglutide’s in pattern though dedicated CKD trials are still in progress.

For heart failure, SUMMIT (Packer 2024, NEJM) tested tirzepatide in 731 adults with HFpEF and obesity. KCCQ scores improved 19.5 points more than placebo, with reduced clinical events and improved six-minute walk distance.

What About Obstructive Sleep Apnea?

SURMOUNT-OSA (Malhotra 2024 NEJM) tested tirzepatide 10-15 mg weekly in 469 adults with moderate to severe obstructive sleep apnea and obesity. The apnea-hypopnea index (AHI) dropped by 25.3 events per hour on drug vs 5.3 on placebo. About 50% of patients reached AHI <5 (effectively cured) on tirzepatide.

FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in obese adults in December 2024. This was the first medication ever approved for OSA. CPAP remains a primary therapy, but tirzepatide offers an alternative or adjunct for many patients.

Key Takeaway: SURMOUNT-1: 20.9% mean weight loss at 72 weeks on 15 mg dose (Jastreboff 2022, NEJM)

What Makes Compounded Tirzepatide Different From Brand?

Compounded tirzepatide contains the same active ingredient as Mounjaro and Zepbound. The molecule is identical. What differs is the manufacturer, the inactive ingredients, the regulatory pathway, and often the concentration.

Brand tirzepatide comes in fixed-dose pens (2.5, 5, 7.5, 10, 12.5, 15 mg). Compounded tirzepatide typically comes in multi-dose vials at concentrations like 10 mg/mL or 20 mg/mL. The drug exposure is the same when the dose is matched. Many compounded preparations include vitamin B12 for nausea and energy support.

Tirzepatide was on the FDA shortage list from 2022 until late 2024. Compounding under shortage was clearly permitted during that period. After removal from shortage, compounding has continued under section 503A for clinically justified individualized prescriptions. TrimRx works with licensed compounding pharmacies and offers a free assessment quiz to determine if compounded tirzepatide is appropriate.

How Long Does It Take Tirzepatide to Start Working?

The drug reaches steady state at about 4 weeks of weekly dosing (4-5 half-lives). Clinically, appetite suppression usually begins within the first 2-3 days of the first injection, even at the 2.5 mg starter dose. The effect strengthens at each titration step.

Average weight loss in SURMOUNT-1 followed this pattern: about 5% at week 12, 12-15% at week 28, and 20.9% at week 72 on the 15 mg dose. Glucose lowering in diabetes is faster, with most of the A1c drop occurring within 12 weeks.

Individual response varies. Roughly 91% of SURMOUNT-1 participants on 15 mg lost ≥5% of body weight, 73% lost ≥15%, and 57% lost ≥20%.

What Happens When You Stop?

SURMOUNT-4 (Aronne 2024 JAMA) tested whether continued tirzepatide vs switching to placebo affects weight maintenance. After 36 weeks of titration, 670 participants continued or switched. The continuation group lost another 5.5% over the next year. The placebo switch group regained 14.0% of body weight.

The pattern matches semaglutide and other GLP-1 drugs: stopping leads to regain over months. Approximately 14% of the lost weight comes back in the first 6-12 months after stopping. Building habits during treatment helps but doesn’t fully prevent regain for most people.

This is why tirzepatide is now treated as a chronic-disease medication for obesity rather than a short course. Long-term maintenance dosing is the standard approach. TrimRx structures plans around the lowest effective long-term maintenance dose.

What’s the Role of GIP Receptor Biology?

GIP was discovered in the 1970s as the first incretin hormone. Like GLP-1, it amplifies insulin response to food. Unlike GLP-1, isolated GIP agonism didn’t lower glucose effectively in type 2 diabetes because chronic insulin resistance affects beta cell response to GIP differently than to GLP-1.

When tirzepatide activates both receptors simultaneously, the GIP effect on insulin secretion is reinforced by the GLP-1 effect. The combination overcomes the GIP resistance seen with isolated GIP agonism. The result is stronger glucose-dependent insulin release than either pathway alone.

GIP also has direct effects on adipose tissue. In animal models, GIP signaling improves adipocyte lipid storage capacity and reduces ectopic fat (fat deposited in liver, muscle, and pancreas). These effects may explain some of tirzepatide’s metabolic benefits beyond weight loss alone.

How Does Tirzepatide Cross the Blood-brain Barrier?

Like semaglutide, tirzepatide accesses the central nervous system primarily through circumventricular organs (area postrema, subfornical organ) where the blood-brain barrier is permeable. From these access points, the drug reaches hypothalamic and brainstem nuclei involved in appetite, satiety, and reward.

The dual receptor activation produces stronger central effects than GLP-1 alone. Functional MRI studies show greater reduction in food-cue-induced reward activation with tirzepatide compared to semaglutide-equivalent doses, consistent with the additive central effect of GIP plus GLP-1 signaling.

This central penetration is why tirzepatide produces appetite suppression and food-noise quieting. Peripheral effects (gastric emptying, peripheral insulin sensitization) contribute but are secondary in importance for weight loss in non-diabetic populations.

What About Effects on Energy Expenditure?

A long-standing question in obesity treatment is whether weight loss drugs only reduce intake or also increase energy expenditure. Most appetite suppressants work through intake reduction; thermogenic compounds increase expenditure.

Tirzepatide appears to do both, though intake reduction dominates. Indirect calorimetry studies in animal models and small human studies suggest tirzepatide may partially blunt the adaptive reduction in resting metabolic rate that normally accompanies weight loss. The exact magnitude is debated, but the effect appears real and somewhat stronger than seen with GLP-1 alone.

This may explain why tirzepatide outperforms semaglutide head-to-head despite similar central appetite effects. Less metabolic adaptation means more of the calorie deficit translates to actual fat loss rather than getting compensated by a slower metabolism.

Bottom line: Dual mechanism reduces both food intake and energy expenditure adaptation more than GLP-1 alone

FAQ

Is Compounded Tirzepatide Chemically the Same as Mounjaro and Zepbound?

The active ingredient is the same molecule. Compounded preparations may use different concentrations and may include additives like B12, but the GIP and GLP-1 receptor binding and downstream mechanism are identical.

Why Does Tirzepatide Produce More Weight Loss Than Semaglutide?

Dual activation of GIP and GLP-1 receptors produces additive effects on appetite, insulin response, and possibly metabolic adaptation. SURMOUNT-1 showed 20.9% weight loss vs STEP 1’s 14.9%, though direct head-to-head SURMOUNT-5 data are still being published.

Does GIP Signaling Cause Weight Gain on Its Own?

Pure GIP agonists weren’t pursued because of mixed early data. In combination with GLP-1 activation, GIP signaling shifts toward weight loss and metabolic benefit. The combined effect doesn’t behave like the sum of two independent agents.

Is the Half-life of Tirzepatide Longer Than Semaglutide?

No, slightly shorter. Tirzepatide half-life is about 117 hours (5 days); semaglutide is 165 hours (7 days). Both support once-weekly dosing comfortably.

Will Tirzepatide Be Approved for Cardiovascular Disease?

SURPASS-CVOT results expected in 2025. If positive, a cardiovascular indication will likely follow. The data so far strongly suggest cardiovascular benefit, but FDA approval requires the specific trial.

Does Tirzepatide Work Better in Some People Than Others?

Yes. Genetic variants in the GIP and GLP-1 receptor genes, baseline insulin sensitivity, body composition, and behavioral factors all influence response. About 36% of SURMOUNT-1 participants on 15 mg lost ≥25% of body weight; others lost much less.

Can I Take Tirzepatide If I Have Type 1 Diabetes?

Off-label use in type 1 diabetes is becoming more common with endocrinology supervision. It’s not FDA-approved for type 1 and requires careful insulin dose management to avoid hypoglycemia and ketoacidosis.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

Related Articles

• Compounded Tirzepatide Switching to or From: Transition Protocols & Dose Conversion
• Compounded Tirzepatide Dosing Guide: Schedule, Titration & What to Expect Each Week
• Compounded Tirzepatide Latest Research: New Indications, Trials & What’s Coming
• Compounded Semaglutide How It Works: Mechanism of Action Explained